Lifordi Immunotherapeutics, Inc., a biotechnology company focused on developing novel treatments for autoimmune and inflammatory disorders, has secured $42,000,000 in new funding from investors. The capital raise marks a significant milestone for the company as it advances its innovative approach to addressing conditions with high unmet medical needs.
Lifordi is pioneering the application of antibody-drug conjugates (ADCs), a technology successfully utilized in oncology, to target specific cells implicated in autoimmune and inflammatory diseases. The company’s strategy involves targeting myeloid and lymphoid cells through a highly internalized cell surface membrane protein. Preclinical studies have demonstrated superior efficacy across multiple disease models, showcasing the potential of their platform to deliver targeted therapies.
This new investment will support the continued advancement of Lifordi's pipeline. The company plans to deploy the capital to expand its research and development efforts, progress its preclinical programs, and move its lead candidates towards initial clinical data. This funding is crucial for supporting the rigorous development required for novel therapeutic candidates in immunology.
With a team of experienced drug developers specializing in immunology and inflammatory diseases, Lifordi aims to significantly impact how these complex conditions are treated. The company previously received funding from ARCH Venture Partners, 5AM Ventures, and Atlas Venture, which has supported its foundational work and preclinical advancements. This latest round reinforces its trajectory.
The successful funding round positions Lifordi Immunotherapeutics for substantial growth and further validates its differentiated approach. The company remains committed to leveraging its expertise and technology to bring transformative therapies to patients suffering from autoimmune and inflammatory diseases, with an outlook towards initiating clinical studies in the near future.
